Lead is one of the most extensively researched man-made contaminants. It has become increasingly clear that this contaminant is not safe in the environment for children’s neurobehavioral development. Despite significant progress in reducing its prevalence over the past few decades, numerous studies have shown that lead exposure results in persistent cognitive impairments and may increase the prevalence of neurodegenerative diseases. A focus is needed on early pharmaceutical interventions that will mitigate the cognitive and behavioral outcomes of lead exposure in children. The present rapid literature review utilized a systematic approach to address the gap in the literature on identifying pharmaceutical interventions to improve cognitive and behavioral outcomes in children exposed to Pb. Using a precise search strategy, 1,536 articles from PubMed were identified and screened via the Preferred Reporting Items for Systematic Reviews and Meta-Analyses process. Upon completion, eight articles were included in this review. Most studies reported a positive effect of their pharmaceutical intervention on Pb-induced toxicity, albeit with varying degrees of evidence. Although available research on medical interventions for lead exposure is limited, the identified pharmaceutical approaches may effectively reduce the harmful effects of lead on health and development. However, further research is needed to establish their effectiveness and appropriate dosages and protocols fully.
Cabanas, Ericka, "Pharmaceutical Approaches to Improve Cognitive and Behavioral Outcomes From Lead Exposure" (2023). Master of Public Health Capstone Presentations. Presentation 487.